Cargando…

Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?

• We summarised immunosuppressing anticancer drugs which could worsen COVID 19 infections. • Other drugs were studied for drug-drug interactions with antiviral medicines. • A ready-to-use table synthesised these interactions between antiviral and anticancer drugs.

Detalles Bibliográficos
Autores principales:	Gougis, Paul, Fenioux, Charlotte, Funck-Brentano, Christian, Veyri, Marianne, Gligorov, Joseph, Solas, Caroline, Spano, Jean-Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284279/ https://www.ncbi.nlm.nih.gov/pubmed/32610172 http://dx.doi.org/10.1016/j.ejca.2020.05.027

Ejemplares similares

Comparaison des caractéristiques et des pronostics des patients avec et sans cancer actif hospitalisés pour une infection à SARS-CoV-2
por: Fenioux, Charlotte, et al.
Publicado: (2021)

Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma
por: Poizot-Martin, Isabelle, et al.
Publicado: (2022)

Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database
por: Nguyen, Lee S., et al.
Publicado: (2020)

Cytochrome P-450-mediated herb and food–drug interactions can be identified in cancer patients through patient self-reporting with a tablet application: results of a prospective observational study
por: Gougis, P., et al.
Publicado: (2022)

Kaposi’s Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition
por: Palich, Romain, et al.
Publicado: (2021)

El drama de los venenos : estudio sobre la sociedad del siglo XVII
por: Funck-Brentano, Frantz, 1862-1947

Lutero
por: Funck-Brentano, Frantz, 1862-1947
Publicado: (1963)

Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy
por: Bertin, Lise, et al.
Publicado: (2021)

Précis du droit des gens /
por: Funck-Brentano, Th. (Théophile), 1830-1906
Publicado: (1900)

RETRACTED: Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?
por: Funck-Brentano, Christian, et al.
Publicado: (2020)

What Can We Demonstrate?
por: Mills, G. A.
Publicado: (1896)

Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients
por: Palich, R., et al.
Publicado: (2021)

Reversal Agents: What We Have and What We Can Expect
por: Ruff, Christian T.
Publicado: (2018)

Enhancer RNA: What we know and what we can achieve
por: Han, Zhenzhen, et al.
Publicado: (2022)

What we can and what we cannot see with extracellular multielectrodes
por: Chintaluri, Chaitanya, et al.
Publicado: (2021)

Drying nano particles solution on an oscillating tip at an air liquid interface: what we can learn, what we can do
por: Bernard, Charlotte, et al.
Publicado: (2007)

The origin of life: what we know, what we can know and what we will never know
por: Pross, Addy, et al.
Publicado: (2013)

Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other?
por: Beltrán Hernández, Irati, et al.
Publicado: (2021)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

How we remember what we can do
por: Declerck, Gunnar
Publicado: (2015)

Sufficient blood, safe blood: can we have both?
por: Bönig, Halvard, et al.
Publicado: (2012)

Early discharge of term neonates: we can do it safely
por: Luciano, R
Publicado: (2015)

What Can We Do to Be Saved?
por: Visanska, Samuel A.
Publicado: (1913)

Retraction and republication: cardiac toxicity of hydroxychloroquine in COVID-19
por: Funck-Brentano, Christian, et al.
Publicado: (2020)

Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases
por: Fabre, Stéphanie, et al.
Publicado: (2020)

What can we teach Lymnaea and what can Lymnaea teach us?
por: Rivi, Veronica, et al.
Publicado: (2021)

INDIAN PSYCHIATRY AT THE CROSSROADS - WHAT WE CAN DO WITH WHAT WE HAVE?1
por: Channabasavanna, S.M.
Publicado: (1992)

The cancer-obesity connection: what do we know and what can we do?
por: Riboli, Elio
Publicado: (2014)

Management of Achilles and patellar tendinopathy: what we know, what we can do
por: Aicale, Rocco, et al.
Publicado: (2020)

Isolated Nocturnal Hypertension: What Do We Know and What Can We Do?
por: Tadic, Marijana, et al.
Publicado: (2020)

Hepatitis of unknown etiology in children: What we know and what we can do?
por: Zhu, Mingyu, et al.
Publicado: (2022)

Ketamine plus Alcohol: What We Know and What We Can Expect about This
por: Kobayashi, Natalia Harumi Correa, et al.
Publicado: (2022)

Geriatric Radiation Oncology: What We Know and What Can We Do Better?
por: Roeder, Falk, et al.
Publicado: (2023)

What do we know about $\gamma/\varphi_3$ today?
por: Gligorov, Vladimir V
Publicado: (2013)

The FIRE AND ICE Trial: What We Know, What We Can Still Learn, and What We Need to Address in the Future
por: Kuck, Karl‐Heinz, et al.
Publicado: (2018)

When Can We Release the Amplatzer Ductal Occluder (ADO) Safely?
por: Ghaderian, Mehdi, et al.
Publicado: (2013)

Safe Drugs Versus Innovative Drugs (Can We Have Both?)
por: Raposo, Vera Lúcia
Publicado: (2020)

Can we abandon foregut exclusion for an ideal and safe metabolic surgery?
por: Widjaja, Jason, et al.
Publicado: (2022)

Cosmic debris: what it is and what we can do about it
por: Powell, Jonathan
Publicado: (2017)

Bone fragility in patients with chronic kidney disease
por: Cohen-Solal, Martine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cv7j7nhr3vhjpcm9d02bjf4arh